Ozempic has been around since December 2017, when the FDA first approved it for treating type 2 diabetes. That makes it roughly seven years old as of 2025. But the story of how it went from a diabetes drug to a cultural phenomenon spans a much shorter window, and the timeline helps explain why it still feels so new.
The FDA Approval Timeline
The FDA approved Ozempic in December 2017 based on results from the SUSTAIN clinical trial program, which began enrolling patients in early 2014. Those trials tested the drug’s ability to lower blood sugar in people with type 2 diabetes, comparing it against both placebo and existing diabetes medications. By the time the FDA gave its approval, thousands of patients had been studied across multiple trials.
The European Union followed shortly after. The European Commission granted marketing authorization for Ozempic on February 8, 2018, making the drug available across EU member states within months of its U.S. launch.
How Its Uses Expanded
Ozempic’s original approval covered blood sugar control in type 2 diabetes, but the FDA expanded its label in January 2020 to include cardiovascular risk reduction. That update meant doctors could prescribe it specifically to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and known heart disease. This was a meaningful expansion because cardiovascular complications are the leading cause of death among people with diabetes.
Meanwhile, Novo Nordisk developed other versions of the same active ingredient. An oral tablet form called Rybelsus received FDA approval for type 2 diabetes as well, giving patients an alternative to weekly injections. Then in June 2021, the FDA approved Wegovy, a higher-dose injectable version of the same compound, specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Wegovy is what formally brought semaglutide into the weight loss conversation, though doctors had already been prescribing Ozempic off-label for that purpose.
When Ozempic Became a Household Name
Even though Ozempic launched in late 2017, it didn’t become a mainstream cultural topic until around 2022 and 2023. Celebrity use, social media buzz, and dramatic before-and-after photos drove enormous public interest, mostly centered on weight loss rather than diabetes management. This surge in demand created real supply problems. Ozempic was added to the FDA’s official drug shortage list on August 23, 2022, less than five years after its approval. The shortage affected people with type 2 diabetes who depended on the drug and suddenly couldn’t fill their prescriptions.
So while Ozempic has technically existed for over seven years, its life as a widely recognized medication is closer to three. The gap between approval and fame explains why many people assume it’s a brand-new drug.
The Semaglutide Family at a Glance
- Ozempic (injection): Approved December 2017 for type 2 diabetes, with a cardiovascular indication added in January 2020.
- Rybelsus (oral tablet): Approved for type 2 diabetes, offering a daily pill instead of a weekly injection.
- Wegovy (injection): Approved June 2021 for chronic weight management at a higher dose than Ozempic.
All three use the same compound but are approved for different purposes and at different doses. Ozempic and Wegovy are not interchangeable prescriptions, even though they contain the same ingredient.
How Long Ozempic Will Stay on the Market
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032. After that, generic and biosimilar versions could enter the market, potentially lowering costs. However, Novo Nordisk has been actively defending its patent portfolio, and settlement agreements with companies challenging those patents may include negotiated entry dates for competitors. The specifics of those deals remain confidential, so the exact timeline for cheaper alternatives is still uncertain.
For now, Ozempic remains under patent protection, and its price reflects that exclusivity. The drug’s first seven years have transformed both the diabetes treatment landscape and public expectations around medical weight loss, a pace of cultural adoption that far outstripped its relatively quiet early years on the market.